Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Voorraadrapport

Marktkapitalisatie: US$4.5b

Alpine Immune Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Alpine Immune Sciences is Mitch Gold, benoemd in Jun2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.92M, bestaande uit 20.5% salaris en 79.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.019% van de aandelen van het bedrijf, ter waarde $ 860.60K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 6.1 jaar.

Belangrijke informatie

Mitch Gold

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris20.5%
Dienstverband CEO7.9yrs
Eigendom CEO0.02%
Management gemiddelde ambtstermijn4.3yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

May 11
Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Sep 20

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Analyse CEO-vergoeding

Hoe is Mitch Gold's beloning veranderd ten opzichte van Alpine Immune Sciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

Compensatie versus markt: De totale vergoeding ($USD 2.92M ) Mitch } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.65M ).

Compensatie versus inkomsten: De vergoeding van Mitch is gestegen terwijl het bedrijf verliesgevend is.


CEO

Mitch Gold (55 yo)

7.9yrs

Tenure

US$2,921,224

Compensatie

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
$ 860.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
$ 19.2m
Paul Rickey
Senior VP7.1yrsUS$1.28mgeen gegevens
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a yeargeen gegevens0.044%
$ 2.0m
M. Yi
Chief Technology Officerless than a yeargeen gegevensgeen gegevens
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno datageen gegevensgeen gegevens
Remy Durand
Chief Business Officer4.3yrsgeen gegevens0.15%
$ 6.6m
Andrew Sandler
Chief Medical Officer1.8yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALPN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
$ 860.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
$ 3.2m
James Topper
Independent Director7.9yrsUS$101.46k0%
$ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
$ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrsgeen gegevensgeen gegevens
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
$ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno datageen gegevensgeen gegevens
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
$ 123.5k
John Thompson
Member of Scientific Advisory Board5.5yrsgeen gegevensgeen gegevens
Manish Butte
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paul Tumeh
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
James Welsh
Member of Scientific Advisory Board5.5yrsgeen gegevensgeen gegevens

6.1yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALPN wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).